These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4395162)

  • 21. Tolerance induction and sensitization by preincubation of bone marrow with allogeneic erythrocytes.
    Uphoff DE
    J Natl Cancer Inst; 1971 Dec; 47(6):1223-31. PubMed ID: 4399195
    [No Abstract]   [Full Text] [Related]  

  • 22. Antilymphoid globulin in the therapy of secondary disease.
    Corneci I; Andrian T; Costachel O; Feteanu A
    Transplant Proc; 1971 Mar; 3(1):422-6. PubMed ID: 4398500
    [No Abstract]   [Full Text] [Related]  

  • 23. Prolonged administration of antithymocyte serum in mice. I. Observations on cellular and humoral immunity.
    Nehlsen SL
    Clin Exp Immunol; 1971 Jul; 9(1):63-77. PubMed ID: 4397709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Graft-versus-host potential of long-term H-2-tolerant parabiosed mice.
    Drell DW; Wegmann TG
    Transplant Proc; 1977 Mar; 9(1):927-30. PubMed ID: 17205
    [No Abstract]   [Full Text] [Related]  

  • 25. [Protective effect of antisera against homograft reaction and other immunologic injuries].
    Benkö A
    Z Gesamte Inn Med; 1971 Aug; 26(15):479-83. PubMed ID: 4110569
    [No Abstract]   [Full Text] [Related]  

  • 26. Modification of the second set reaction by antilymphocytic serum.
    Boak JL; Draper V; House AK; Pattisson PH
    Br J Surg; 1971 Apr; 58(4):300-1. PubMed ID: 4396709
    [No Abstract]   [Full Text] [Related]  

  • 27. Lymphocyte environment and the durability of transplantation tolerance.
    Levey RH
    Transplant Proc; 1972 Sep; 4(3):395-9. PubMed ID: 4404152
    [No Abstract]   [Full Text] [Related]  

  • 28. [Suppression of primary and secondary immune response by antilymphocyte serum, shown by antigen-specific proliferation activity in graft-vs-host model].
    Baumann P; Thierfelder S
    Blut; 1974 Jan; 28(1):51-5. PubMed ID: 4149351
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prevention of the graft vs host reaction in rats by means of allogeneic antilymphocyte serum following bone marrow transplantation].
    Jeannet M; Vaucher A; Gervasoni C
    Schweiz Med Wochenschr; 1972 Nov; 102(44):1598-600. PubMed ID: 4405059
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of allogenic, homozygous bone marrow cells for the induction of specific immunologic tolerance in mice treated with antilymphocyte serum.
    Gozzo JJ; Wood ML; Monaco AP
    Surg Forum; 1970; 21():281-4. PubMed ID: 4936984
    [No Abstract]   [Full Text] [Related]  

  • 31. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration.
    Lehnert S; Rybka WB
    Bone Marrow Transplant; 1994 Apr; 13(4):473-7. PubMed ID: 8019473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of acute graft-versus-host (GVH) mortality with spleen-absorbed antithymocyte globulin (ATG).
    Trentin JJ; Judd KP
    Transplant Proc; 1973 Mar; 5(1):865-8. PubMed ID: 4540468
    [No Abstract]   [Full Text] [Related]  

  • 33. Selective effects of heterospecific antilymphocyte sera on graft and host components in graft-versus-host reactions.
    Brune K; Floersheim GL
    Agents Actions; 1970 Mar; 1(3):112-4. PubMed ID: 4398593
    [No Abstract]   [Full Text] [Related]  

  • 34. The theory, practice and treatment of graft versus host reactions.
    Nouza K
    Rev Fr Etud Clin Biol; 1968 Oct; 13(8):747-62. PubMed ID: 4886386
    [No Abstract]   [Full Text] [Related]  

  • 35. Synergistic effect of antilymphocyte serum and the graft-versus-host reaction on murine skin allograft survival.
    Lapp WS
    Transplantation; 1973 May; 15(5):469-73. PubMed ID: 4145550
    [No Abstract]   [Full Text] [Related]  

  • 36. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity.
    Yamamoto S; Tsuji T; Matsuzaki J; Zhange Y; Chamoto K; Kosaka A; Togashi Y; Sekikawa K; Sawada K; Takeshima T; Koike T; Nishimura T
    Int Immunol; 2004 Jun; 16(6):811-7. PubMed ID: 15126416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Host and graft factors in the homing of haematopoietic cells.
    Hasek M; Nouza K
    Hamatol Bluttransfus; 1970; 9():79-85. PubMed ID: 4396278
    [No Abstract]   [Full Text] [Related]  

  • 38. Modification of corneal homograft rejection by donor pretreatment with antilymphocyte serum.
    Lernor RE; Burde RM; Waltman SR
    Am J Ophthalmol; 1970 Mar; 69(3):453-7. PubMed ID: 4392176
    [No Abstract]   [Full Text] [Related]  

  • 39. Indefinite survival following small intestinal transplantation after intrathymic injection of the donor with recipient-type splenocytes in a rat model.
    Blakely ML; Shaffer D; Ohzato H; Gottschalk R; Van der Werf WJ; Monaco AP
    Transplantation; 1995 Jan; 59(2):309-11. PubMed ID: 7839457
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and pathologic characteristics of graft-versus-host disease produced in cyclophosphamide-treated adult mice.
    Sandberg JS; Owens AH; Santos GW
    J Natl Cancer Inst; 1971 Jan; 46(1):151-60. PubMed ID: 4395991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.